Serum Catestatin Expression and Cardiometabolic Parameters in Patients With Congestive Heart Failure
NCT03389386 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120
Last updated 2019-04-17
Summary
The congestive heart failure (HF) is a condition associated with substantial morbidity, mortality, and high healthcare expenditures. From the pathophysiological standpoint, several mechanisms contribute to the progression and dysfunction of the failing heart such as an increased hemodynamic overload, impaired myocyte calcium cycling, upregulated apoptotic activity, deficient or increased production of extracellular matrix, genetic predilections and, finally, excessive neurohumoral stimulation. The vasoactive neurohumoral systems such as sympathetic nervous system, renin-angiotensin-aldosterone system (RAAS) and arginine vasopressin (AVP) system all play a role in maintaining volume and circulatory homeostasis in the situation of impaired cardiac output.
Catestatin (CST), on another hand, is a novel endogenous peptide cleaved from chromogranin A (CgA) that is involved in the regulation of cardiac function and arterial blood pressure. The role of this peptide is to elicit potent catecholamine release-inhibitory activity by acting at the level of the nicotinic acetylcholine receptors. Therefore, the main hypothesis of this study is that the observed serum CST levels will reflect the degree of neurohormonal activation in HF, showing a significant relationship with the degree of disease severity as measured by relevant functional classifications (such as NYHA class and/or similar). Secondly, investigators expect to detect correlation of catestatin serum levels with the established risk stratification scores in HF and with the echocardiographic parameters of the ventricular function, both in terms of systolic and diastolic cardiac function. Parameters of inflammation, NT-proBNP, hs-cTnI, renal function parameters, and basic hematologic/biochemistry indices from peripheral blood will also be obtained and analyzed for all study participants.
Furthermore, according to the latest European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of acute and chronic HF, participants with established congestive HF and the whole spectrum of left ventricular ejection fractions ranging from \<40% to ≥50% will be included in the study.
Finally, all echocardiographic and laboratory parameters obtained from peripheral blood will be recorded and compared with respective healthy and matched control participants while participants diagnosed with HF will additionally be analyzed for potential differences between subgroups of interest.
Conditions
- Heart Failure,Congestive
Interventions
- DIAGNOSTIC_TEST
-
Blood withdrawal for laboratory analysis
Participants in this study will have their peripheral blood sampled from the cubital vein and the total volume withdrawn for the purposes of this study will be no more than 22 mL per person. Parameters of interest in the laboratory analysis will include serum catestatin levels, NT-proBNP levels, hs-cTnI, parameters of inflammation and renal function as well as standard biochemistry and complete blood count (CBC) panels.
- OTHER
-
Standard-of-care treatment
Patients diagnosed with chronic heart failure will receive optimal standards of care in terms of pharmacologic management, according to their current clinical condition.
- DIAGNOSTIC_TEST
-
Transthoracic echocardiography (TTE)
Participants from both groups will undergo transthoracic echocardiography examination that will measure established hemodynamic parameters of systolic and diastolic cardiac function as well as parameters of LV and RV strain in the selected subset of patients.
Sponsors & Collaborators
-
University of Split, School of Medicine
collaborator OTHER -
Josko Bozic
lead OTHER
Principal Investigators
-
Josko Bozic, MD, PhD · Department of Pathophysiology, University of Split School of Medicine
Eligibility
- Min Age
- 35 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-01-25
- Primary Completion
- 2019-04-16
- Completion
- 2019-04-16
Countries
- Croatia
Study Locations
More Related Trials
-
MAP( Mean Arterial Pressure) and Mortality Relation in Patients With Heart Failure
NCT06515366 ·Status: RECRUITING
-
Tissue Factor Expression in Stage C Heart Failure
NCT00935740 ·Status: COMPLETED
-
Assessment of Functional Capacity and Inflammatory Markers in Women With Heart Failure With Preserved Ejection Fraction
NCT02649400 ·Status: UNKNOWN
-
Insulin Resistance : Heart Failure
NCT00486967 ·Status: COMPLETED
-
Strain X Cardiopulmonary Test
NCT02869178 ·Status: UNKNOWN
-
The Biomarker and Cardiac Function in Sepsis
NCT00800631 ·Status: UNKNOWN
-
Pronostic Value of Endothelial Dysfunction in Heart Failure
NCT02859636 ·Status: TERMINATED
-
Congestive Heart Failure Surgical Treatmment With Autologous Stem Cell Therapy
NCT00480961 ·Status: UNKNOWN ·Phase: PHASE2
-
Acute Cardiac Dysfunction in Critical Illnes
NCT05860504 ·Status: RECRUITING
-
CTO-PCI in Heart Failure Patients
NCT05632653 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Analysis of Incidence and Risk Factors of Severe Cardiovascular Events in Patients With Diastolic Dysfunction
NCT03138109 ·Status: COMPLETED
-
The TOSCA Registry: Hormonal and Metabolic Deficiencies in Chronic Heart Failure
NCT02335801 ·Status: UNKNOWN
-
The Role and Dynamics of Liver Dysfunction in Patients Undergoing Cardiac Surgery
NCT02893657 ·Status: UNKNOWN
-
Clinical, Functional, Immunological and Genetic Factors on the Severity of the Course of Coronavirus Infection
NCT04987853 ·Status: UNKNOWN
-
Reversal of Obesity Cardiomyopathy
NCT01372397 ·Status: COMPLETED
-
Oxidative Stress Markers and Cardiac Resynchronization Therapy (CRT) Outcomes
NCT01151553 ·Status: TERMINATED ·Phase: NA
-
Therapeutic Thoracentesis for Patients With Congestive Heart Failure and Large Pleural Effusion
NCT00629538 ·Status: COMPLETED ·Phase: NA
-
Immunometabolic Pattern of Intermittent Hypoxia During ST-segment Elevation Myocardial Infarction
NCT05230966 ·Status: UNKNOWN ·Phase: NA
-
The Impact of Menopause on the Development of Heart Failure and Organ Damage of Hypertension
NCT04822857 ·Status: COMPLETED
-
Atrial Fibrillation Risk After Miniinvasive Mitral Valve Repair
NCT06707506 ·Status: COMPLETED
-
New Biomarkers in Heart- and Renal Failure
NCT02830464 ·Status: COMPLETED
-
Hepatocyte Growth Factor (HGF) Concentration in Myocardial Infarction
NCT01233336 ·Status: COMPLETED
-
Study of the Clinical Scoring System and Cytokines for Prediction of Inflammatory Response in Major Surgery
NCT01353157 ·Status: COMPLETED
-
Change of NLRP3 Inflammasome Expression Level, Symptoms, and Functional Status in HFpEF Patients Treated With ARNI
NCT04269057 ·Status: UNKNOWN
-
Clinical Characteristics and Outcomes Among STEMI Patients With Cardiogenic Shock at Abu Dhabi City
NCT06535503 ·Status: RECRUITING